Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

116.55 +0.52 (+0.45%)
Official Closing Price Updated: 4:10 PM EDT, Aug 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,199,496
Open 116.30
Bid (Size) 116.64 (3)
Ask (Size) 116.67 (3)
Prev. Close 116.03
Today's Range 115.22 - 116.72
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
Merck's rVSV-ZEBOV vaccine, the only WHO-prequalified vaccine for Ebola outbreaks caused by the Zaire ebolavirus, is FDA-approved for adults and children. A study on the 2018–20 Congo outbreak shows... 
Via Benzinga
Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping?
Merck's wider drug moat and acquisition spree makes it a safer bet but VKTX can be the next LLY. 
Via Talk Markets

Performance

YTD
+2.92%
+2.92%
1 Month
-7.27%
-7.27%
3 Month
-11.10%
-11.10%
6 Month
-9.03%
-9.03%
1 Year
+8.69%
+8.69%

More News

Read More
Biotech Bull Market: 3 Ways To Play It
Via Talk Markets
Topics Economy
Exposures Interest Rates
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Merck & Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
In-Depth Analysis: Merck & Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
Via Chartmill
Looking Into Merck & Co's Recent Short Interest
Via Benzinga
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Via MarketBeat
Exposures COVID-19 Product Safety
These 3 Healthcare Companies Had the Top-Selling Drugs Last Year
Via The Motley Fool
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
Via Benzinga
Topics Economy
Exposures Interest Rates
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Via Investor's Business Daily
2 Dow Jones Stocks to Buy Hand Over Fist Right Now
Via The Motley Fool
Topics Economy Stocks
Exposures Economy US Equities
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
Via InvestorPlace
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck's $1.3B Deal For Potential Autoimmune Disorder Candidate Is Relevant To Cullinan's Investigational Drug, Says Analyst
Via Benzinga
'I'm Not Proud Of Myself': Jim Cramer Says He Bought 'Worst Of The Three' GE Stocks
Via Benzinga
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
From Merck & Co., Inc.
Via Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
Via Investor Brand Network
Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects
Via Benzinga
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
The 3 Best Biotech Stocks to Buy in August 2024
Via InvestorPlace
NYSE:MRK is an undervalued gem with solid fundamentals.
Via Chartmill
Palantir’s AI Evolution: Strategic Shift Or Marketing Ploy?
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.